Author: ALX Oncology

Posted Date:

April 13, 2026

ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer

ALX Oncology

April 13, 2026
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

ALX Oncology

February 27, 2026
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026

ALX Oncology

February 19, 2026
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026

ALX Oncology

February 19, 2026
ALX Oncology Announces Pricing of Underwritten Offering

ALX Oncology

January 30, 2026
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer

ALX Oncology

January 30, 2026